You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Colorcon
Express Scripts
Medtronic
McKesson

Last Updated: December 5, 2023

Oliceridine - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for oliceridine and what is the scope of patent protection?

Oliceridine is the generic ingredient in one branded drug marketed by Trevena and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Oliceridine has fifty-one patent family members in twenty-three countries.

One supplier is listed for this compound.

Summary for oliceridine
International Patents:51
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 32
Clinical Trials: 5
Patent Applications: 139
What excipients (inactive ingredients) are in oliceridine?oliceridine excipients list
DailyMed Link:oliceridine at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for oliceridine
Generic Entry Date for oliceridine*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for oliceridine

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of TennesseePhase 4
Trevena Inc.Phase 4
The Cleveland ClinicPhase 3

See all oliceridine clinical trials

US Patents and Regulatory Information for oliceridine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-002 Oct 30, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-003 Oct 30, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-002 Oct 30, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-001 Oct 30, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-003 Oct 30, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for oliceridine

Country Patent Number Title Estimated Expiration
Poland 2688403 ⤷  Try a Trial
Japan 2016155843 オピオイド受容体リガンド並びにそれらの使用方法及び製造方法 (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING THE SAME) ⤷  Try a Trial
Japan 6649341 ⤷  Try a Trial
South Korea 102129247 ⤷  Try a Trial
Cyprus 1119057 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Merck
Mallinckrodt
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.